Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/105456
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHew, Meilyn-
dc.contributor.authorO'Connor, Kevin-
dc.contributor.authorEdel, Michael John-
dc.contributor.authorLucas, Michaela-
dc.date.accessioned2017-01-11T14:58:11Z-
dc.date.available2017-01-11T14:58:11Z-
dc.date.issued2015-05-28-
dc.identifier.issn2077-0383-
dc.identifier.urihttp://hdl.handle.net/2445/105456-
dc.description.abstractThe ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm4061193-
dc.relation.ispartofJournal of Clinical Medicine, 2015, vol. 4, num. 6, p. 1193-1206-
dc.relation.urihttps://doi.org/10.3390/jcm4061193-
dc.rightscc-by (c) Hew, Meilyn et al., 2015-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Biomedicina)-
dc.subject.classificationCèl·lules mare-
dc.subject.classificationAutoimmunitat-
dc.subject.classificationTeràpia cel·lular-
dc.subject.otherStem cells-
dc.subject.otherAutoimmunity-
dc.subject.otherCellular therapy-
dc.titleThe possible future roles for IPSC-Derived therapy for Autoimmune Diseases.-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec653307-
dc.date.updated2017-01-11T14:58:11Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid26239553-
Appears in Collections:Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
653307.pdf121.34 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons